Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 2
1988 14
1989 18
1990 12
1991 14
1992 14
1993 14
1994 24
1995 25
1996 27
1997 20
1998 28
1999 41
2000 45
2001 51
2002 64
2003 51
2004 67
2005 58
2006 77
2007 67
2008 83
2009 96
2010 124
2011 115
2012 121
2013 135
2014 223
2015 282
2016 304
2017 344
2018 316
2019 374
2020 390
2021 303
Text availability
Article attribute
Article type
Publication date

Search Results

3,535 results
Results by year
Filters applied: . Clear all
Page 1
Breast cancer in adolescents and young adults.
Johnson RH, Anders CK, Litton JK, Ruddy KJ, Bleyer A. Johnson RH, et al. Pediatr Blood Cancer. 2018 Dec;65(12):e27397. doi: 10.1002/pbc.27397. Epub 2018 Aug 28. Pediatr Blood Cancer. 2018. PMID: 30156052 Free PMC article. Review.
Breast cancer is the most common cancer of adolescents and young adult (AYA) women aged 15 to 39 years, accounting for 5.6% of all invasive breast cancer in women. In comparison with older women, AYAs are more likely to have familial cancer
Breast cancer is the most common cancer of adolescents and young adult (AYA) women aged 15 to 39 years, accounting for
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R. Gradishar WJ, et al. J Natl Compr Canc Netw. 2020 Apr;18(4):452-478. doi: 10.6004/jnccn.2020.0016. J Natl Compr Canc Netw. 2020. PMID: 32259783
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-re …
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to impro …
Pathology of breast cancer in the last half century.
Solanki M, Visscher D. Solanki M, et al. Hum Pathol. 2020 Jan;95:137-148. doi: 10.1016/j.humpath.2019.09.007. Epub 2019 Nov 1. Hum Pathol. 2020. PMID: 31682887 Review.
Pathologists, with the support of epidemiologists, have lead significant advancements in the description and clinical significance of benign breast disease. Despite considerable efforts, the cure for breast cancer awaits better understanding of the pathophysi …
Pathologists, with the support of epidemiologists, have lead significant advancements in the description and clinical significance of benign …
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK; Alliance for Clinical Trials in Oncology. Boughey JC, et al. JAMA. 2013 Oct 9;310(14):1455-61. doi: 10.1001/jama.2013.278932. JAMA. 2013. PMID: 24101169 Free PMC article. Clinical Trial.
IMPORTANCE: Sentinel lymph node (SLN) surgery provides reliable nodal staging information with less morbidity than axillary lymph node dissection (ALND) for patients with clinically node-negative (cN0) breast cancer. The application of SLN surgery for staging the ax …
IMPORTANCE: Sentinel lymph node (SLN) surgery provides reliable nodal staging information with less morbidity than axillary lymph node disse …
Psychosocial interventions in breast cancer survivorship care.
Gudenkauf LM, Ehlers SL. Gudenkauf LM, et al. Breast. 2018 Apr;38:1-6. doi: 10.1016/j.breast.2017.11.005. Epub 2017 Nov 21. Breast. 2018. PMID: 29169071 Review.
Cancer distress screening and subsequent referral for psychosocial intervention has been mandated for continued cancer center accreditation. ...In randomized clinical trials, specific interventions have also been associated with biological improvements, including ne
Cancer distress screening and subsequent referral for psychosocial intervention has been mandated for continued cancer center
The timing of breast and axillary surgery after neoadjuvant chemotherapy for breast cancer.
Al-Hilli Z, Boughey JC. Al-Hilli Z, et al. Chin Clin Oncol. 2016 Jun;5(3):37. doi: 10.21037/cco.2016.03.26. Epub 2016 Apr 22. Chin Clin Oncol. 2016. PMID: 27164853 Free article. Review.
Neoadjuvant chemotherapy (NAC) has traditionally been used in locally advanced and inflammatory breast cancer, allowing for a reduction in disease volume and therefore optimizing surgical resection of disease in the breast. ...The aim of this review is to dis …
Neoadjuvant chemotherapy (NAC) has traditionally been used in locally advanced and inflammatory breast cancer, allowing for a …
Benign breast disease and the risk of breast cancer.
Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW. Hartmann LC, et al. N Engl J Med. 2005 Jul 21;353(3):229-37. doi: 10.1056/NEJMoa044383. N Engl J Med. 2005. PMID: 16034008 Free article.
BACKGROUND: Benign breast disease is an important risk factor for breast cancer. We studied a large group of women with benign breast disease to obtain reliable estimates of this risk. ...In the first 10 years after the initial biopsy, an excess of can …
BACKGROUND: Benign breast disease is an important risk factor for breast cancer. We studied a large group of women with …
A contemporary review of male breast cancer: current evidence and unanswered questions.
Leon-Ferre RA, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, Hawse JR, Boughey JC, Ruddy KJ. Leon-Ferre RA, et al. Cancer Metastasis Rev. 2018 Dec;37(4):599-614. doi: 10.1007/s10555-018-9761-x. Cancer Metastasis Rev. 2018. PMID: 30232577 Review.
Male breast cancer is rare, accounting for 1% of all breast cancer diagnoses in the USA. Because of its rarity, most major breast cancer trials have included only female patients. This has resulted in limited prospective data to guide the …
Male breast cancer is rare, accounting for 1% of all breast cancer diagnoses in the USA. Because of its rarity, …
Available and emerging molecular markers in the clinical management of breast cancer.
Giridhar KV, Liu MC. Giridhar KV, et al. Expert Rev Mol Diagn. 2019 Oct;19(10):919-928. doi: 10.1080/14737159.2019.1664901. Epub 2019 Sep 23. Expert Rev Mol Diagn. 2019. PMID: 31498011 Review.
Areas covered: In early-stage breast cancer, we focus on dynamic changes in Ki-67 during neoadjuvant endocrine therapy and multigene prognostic assays to guide adjuvant chemotherapy decisions. ...Expert opinion: Biomarkers influence breast cancer manag …
Areas covered: In early-stage breast cancer, we focus on dynamic changes in Ki-67 during neoadjuvant endocrine therapy and mul …
Evolving standards of care and new challenges in the management of HER2-positive breast cancer.
Choong GM, Cullen GD, O'Sullivan CC. Choong GM, et al. CA Cancer J Clin. 2020 Sep;70(5):355-374. doi: 10.3322/caac.21634. Epub 2020 Aug 19. CA Cancer J Clin. 2020. PMID: 32813307 Free article. Review.
The management of human epidermal growth factor receptor (HER2)-positive breast cancer (BC) has rapidly evolved over the last 20 years. Major advances have led to US Food and Drug Administration approval of 7 HER2-targeted therapies for the treatment of early-stage …
The management of human epidermal growth factor receptor (HER2)-positive breast cancer (BC) has rapidly evolved over the last …
3,535 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page